Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea

BACKGROUND: Nilotinib is a tyrosine kinase inhibitor approved by the Ministry of Food and Drug Safety for frontline and 2nd line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph(+) CML). This study aimed to confirm the safety and efficacy of nilotinib in routine clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Seo-Yeon, Son, Sang Kyun, Lee, Gyu Hyung, Kim, Inho, Cheong, June-Won, Lee, Won Sik, Kim, Byung Soo, Jo, Deog-Yeon, Jung, Chul Won, Seong, Chu Myoung, Lee, Jae Hoon, Yuh, Young Jin, Kim, Min Kyoung, Ryoo, Hun-Mo, Park, Moo-Rim, Cho, Su-Hee, Kim, Hoon-Gu, Zang, Dae Young, Park, Jinny, Kim, Hawk, Lee, Seryeon, Kim, Sung-Hyun, Chang, Myung Hee, Lee, Ho Sup, Choi, Chul Won, Kwon, Jihyun, Lim, Sung-Nam, Oh, Suk-Joong, Joo, Inkyung, Kim, Dong-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242833/
https://www.ncbi.nlm.nih.gov/pubmed/35678158
http://dx.doi.org/10.5045/br.2022.2021137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242833/
https://www.ncbi.nlm.nih.gov/pubmed/35678158
http://dx.doi.org/10.5045/br.2022.2021137

Ejemplares similares